Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
10.51
+0.44 (4.37%)
At close: Aug 4, 2026, 4:00 PM EDT
10.45
-0.06 (-0.57%)
Pre-market: Aug 5, 2026, 4:39 AM EDT
Candel Therapeutics Employees
Candel Therapeutics had 55 employees as of December 31, 2025. The number of employees increased by 17 or 44.74% compared to the previous year.
Employees
55
Change (1Y)
17
Growth (1Y)
44.74%
Revenue / Employee
n/a
Profits / Employee
-$989,491
Market Cap
770.07M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 55 | 17 | 44.74% |
| Dec 31, 2024 | 38 | -4 | -9.52% |
| Dec 31, 2023 | 42 | -34 | -44.74% |
| Dec 31, 2022 | 76 | 11 | 16.92% |
| Dec 31, 2021 | 65 | 24 | 58.54% |
| Mar 31, 2021 | 50 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pharming Group | 407 |
| Phathom Pharmaceuticals | 371 |
| Rigel Pharmaceuticals | 174 |
| Aura Biosciences | 113 |
| Aclaris Therapeutics | 73 |
| SpyGlass Pharma | 68 |
| Oculis Holding AG | 60 |
| Faeth Therapeutics | 29 |
CADL News
- 1 day ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 1 day ago - Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026 - GlobeNewsWire
- 6 days ago - Candel Therapeutics to Present at Canaccord Genuity's 46th Annual Growth Conference in Boston - GlobeNewsWire
- 23 days ago - Candel Therapeutics initiated with a Buy at Stifel - TheFly
- 27 days ago - Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Candel Therapeutics Slides: Corporate presentation - Filings
- 5 weeks ago - Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors - GlobeNewsWire
- 5 weeks ago - Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer - GlobeNewsWire